Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3Myeloid 2Lymphoid 2Genitourinary 2CNS 2Breast 2Tumor-Agnostic 1Gynecologic 1

Conditions

Breast Neoplasms 2Sarcoma 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Paclitaxel 162Fulvestrant 157Trastuzumab 156pembrolizumab 146Letrozole 137Carboplatin 118pertuzumab 104Capecitabine 104Specimen Handling 102Cyclophosphamide 102Anastrozole 90palbociclib 86abemaciclib 82Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 74trastuzumab deruxtecan 68Radiotherapy 62Biopsy 59Surveys and Questionnaires 55Gemcitabine 53130-nm albumin-bound paclitaxel 53olaparib 52sacituzumab govitecan 51Blood Specimen Collection 51Standard of Care 49Taxes 48eribulin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
LY3023414 × Breast × 1 year × Clear all
NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Eli Lilly and Company

Phase 1 Active not recruiting
198 enrolled
Breast

Breast Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡